Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.
February 20 2024 - 8:01AM
Business Wire
Using de-identified data for 53 million unique
cardiovascular patients, the report examines prevalence across all
50 states and a variety of demographics
Which region of the U.S. has the highest rates of hypertension,
coronary artery disease and heart failure? The South, according to
this analysis on cardiovascular disease (CVD) from Veradigm Inc.
(NASDAQ: MDRX), a leading provider of healthcare data and
technology solutions. Veradigm today released its inaugural
Veradigm Insights Report: Cardiovascular Conditions in 2024, which
examines de-identified real world data for 53 million unique
cardiovascular patients. The report explores the prevalence of CVD
and underlying conditions across all 50 states and a variety of
demographics, including age, ethnicity, and sex.
Using structured and unstructured data from the comprehensive
Veradigm Network EHR dataset, the report presents cardiovascular
condition prevalence by state and three-digit zip code. Veradigm
also examines the prevalence of cardiovascular conditions such as
dyslipidemia/hyperlipidemia and hypertension in relation to body
mass index (BMI) categories.
Findings in this report are derived from the Veradigm Network
EHR database, which connects over 400,000 healthcare providers and
200 million patients. It incorporates structured and unstructured
data using Natural Language Processing (NLP) on approximately
100,000 U.S.-based healthcare practitioners and over 145 million
patients with clinical activity.
“Veradigm is using NLP to extract typically inaccessible
unstructured and semi-structured data. This has been quite
impactful for left ventricle ejection fraction (LVEF),” said
Machaon Bonafede, Vice President of Real-World Evidence at
Veradigm. “NLP on unstructured clinical notes provides LVEF data on
approximately 200,000 additional patients compared to what we can
find in structured fields alone. This type of insight can help
improve management of patients with cardiovascular disease and add
clinical depth to our research.”
In the report, LVEF data pulled from unstructured clinical notes
revealed almost 20,000 patients with possible heart failure and
almost 30,000 with low function in the dataset. This type of
previously inaccessible insight can help improve management of
patients with cardiovascular disease and offers implications for
early intervention.
“Cardiovascular disease is the leading cause of death across
most segments of the population – men, women, and people of most
racial and ethnic groups – in the U.S.,” said Stuart Green,
Veradigm’s Senior Vice President and General Manager of Life
Sciences. “Findings from Veradigm’s repository of de-identified
data provides a larger story about the state of cardiovascular
disease in the United States. We believe this data can help
healthcare organizations to better understand geographic prevalence
of cardiovascular disease and provide an entry point to data that
isn’t typically accessible from other sources. This report affirms
Veradigm’s role as a leader of this important and impactful
data.”
The data in this report were selected and mapped for states and
3-digit zip codes for a subset of 53 million patients in the
Veradigm Network EHR database with evidence of cardiovascular risk
factors or conditions. Veradigm has a variety of additional data
sources including clinically enriched Veradigm Network EHR Data
across various therapeutic areas and the Veradigm Cardiovascular
and Metabolic Registries.
To download the report and learn more about the research, please
visit: Veradigm Insights Report: Cardiovascular Conditions in
2024.
About Veradigm®
Veradigm is a healthcare technology company that drives value
through its unique combination of platforms, data, expertise,
connectivity, and scale. The Veradigm Network features a dynamic
community of solutions and partners providing advanced insights,
technology, and data-driven solutions for the healthcare provider,
payer, and biopharma markets. For more information about how
Veradigm is fulfilling its mission of Transforming Health,
Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn,
Facebook, Twitter, and YouTube.
© 2024 Veradigm Inc. and/or its affiliates. All Rights
Reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220938851/en/
Investors: Jenny Gelinas
312-506-1237 jenny.gelinas@veradigm.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@veradigm.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Apr 2024 to May 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From May 2023 to May 2024